{"id":"NCT00370071","sponsor":"Bayer","briefTitle":"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","officialTitle":"Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2006-08-30","resultsPosted":"2010-02-10","lastUpdate":"2015-10-29"},"enrollment":39,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]}],"arms":[{"label":"Interferon beta-1b (Betaseron, BAY86-5046)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.","primaryOutcome":{"measure":"Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly Active Lesions During 3-month Pre-treatment","timeFrame":"after 6 months of treatment as compared to 3-month pre-treatment","effectByArm":[{"arm":"Interferon Beta-1b (Betaseron, BAY86-5046)","deltaMin":-1.5,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":3,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Influenza like illness","Hepathic function abnormal","Headache","Myalgia","Injection site pain"]}}